Wockhardt Ltd

Wockhardt Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 18 May 2026. While the rating change occurred on that date, the analysis and financial metrics discussed here reflect the stock's current position as of 10 June 2026, providing investors with an up-to-date view of the company’s performance and outlook.

Wockhardt Ltd, a prominent player in the Pharmaceuticals & Biotechnology sector, has emerged as one of the most actively traded stocks by value on 4 June 2026. The stock demonstrated notable strength with a 1.36% gain during early trading hours, supported by strong institutional interest and sustained buying momentum that has propelled it above key moving averages.

The Sensex declined by 0.62% on 03 Jun 2026, while Wockhardt Ltd surged 7.81%, marking a remarkable 8.35 percentage-point outperformance against its Pharmaceuticals & Biotechnology sector. This sharp intraday advance to Rs 2147, representing a 9.06% high, signals a significant shift in the stock’s short-term momentum.

Wockhardt Ltd, a prominent player in the Pharmaceuticals & Biotechnology sector, has witnessed significant trading activity with a notable surge in value turnover and institutional participation. The stock outperformed its sector and broader market indices, reflecting renewed investor confidence and positive momentum following a recent upgrade in its Mojo Grade.

Wockhardt Ltd experienced a notable decline today, touching an intraday low of Rs 2,005.15, reflecting a 6.82% drop from its previous close. The stock underperformed its sector and broader market indices amid prevailing market pressures and a reversal after a sustained rally.

Wockhardt Ltd, a prominent player in the Pharmaceuticals & Biotechnology sector, witnessed significant trading activity on 2 June 2026, marked by a substantial value turnover of over ₹33,236 lakhs. Despite this high liquidity and rising investor participation, the stock price declined sharply by 6.16%, underperforming both its sector and the broader Sensex index.

Wockhardt Ltd witnessed a remarkable surge in trading activity on 1 June 2026, emerging as one of the most actively traded stocks by value in the Pharmaceuticals & Biotechnology sector. The stock soared to a new 52-week high, buoyed by strong institutional participation and robust order flow, signalling renewed investor confidence in this small-cap pharmaceutical player.

With a decisive surge to Rs 2420 on 1 Jun 2026, Wockhardt Ltd has reached a fresh 52-week high, marking a remarkable 54.32% gain over the past year. This rally stands in stark contrast to the Sensex’s 7.99% decline over the same period, underscoring the stock’s strong momentum amid a mixed market backdrop.

The Sensex edged up by a modest 0.3% while Wockhardt Ltd surged 11.09% on 1 Jun 2026, hitting a fresh 52-week high of Rs 2420. This 13.01 percentage-point outperformance over the Pharmaceuticals & Biotechnology sector signals a distinctly stock-specific rally rather than a broad market lift.

Wockhardt Ltd, a prominent player in the Pharmaceuticals & Biotechnology sector, achieved a significant milestone on 1 June 2026 as its stock price surged to an all-time high of Rs. 2,420. This landmark event underscores the company’s robust market performance and sustained upward momentum over recent months.

Wockhardt Ltd commenced trading on 1 June 2026 with a notable gap up, opening 17.1% higher than its previous close, signalling robust market enthusiasm. The stock reached a new 52-week high of Rs. 2,420 during the session, outperforming its sector and broader indices amid sustained upward momentum.

Wockhardt Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 18 May 2026. While the rating change occurred on that date, the analysis and financial metrics discussed here reflect the company’s current position as of 30 May 2026, providing investors with the most up-to-date view of the stock’s fundamentals, returns, and technical outlook.

Wockhardt Ltd, a prominent player in the Pharmaceuticals & Biotechnology sector, witnessed a remarkable surge in trading activity on 29 May 2026, driven by substantial value turnover and heightened institutional participation. The stock not only hit a new 52-week high but also outperformed its sector and broader market indices, signalling renewed investor confidence amid a sustained upward momentum.

With a decisive surge to Rs 1975.5 on 29 Jun 2026, Wockhardt Ltd has reached a fresh 52-week high, marking a 41.29% gain over the past year and significantly outperforming the Sensex, which declined 7.00% in the same period. This rally is underpinned by a strong alignment of technical indicators and sustained price momentum across multiple timeframes.

Wockhardt Ltd witnessed a robust start to trading on 29 May 2026, opening with a significant gap up of 7.82%, signalling strong positive momentum in the Pharmaceuticals & Biotechnology sector. The stock’s performance today notably outpaced the broader market and its sector peers, continuing a sustained upward trend over recent sessions.

The Sensex remained flat on 29 May 2026, while Wockhardt Ltd surged 7.46% to touch an intraday high of Rs 1975.5. This 7.37 percentage-point outperformance over the Pharmaceuticals & Biotechnology sector highlights a distinctly stock-specific rally rather than a broad market move.

Wockhardt Ltd has demonstrated a marked shift in technical momentum, moving from a mildly bullish to a bullish stance, supported by robust price action and improving technical indicators. The stock’s recent performance outpaces the broader market, signalling renewed investor confidence in this small-cap pharmaceutical player.